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Summary 
The 2009 A/H1N1 influenza pandemic was responsible for considerable global morbidity and 
mortality. In 2009, UK funders, including the National Institute for Health Research (NIHR) 
rapidly funded and activated a number of research studies to inform clinical and public health 
actions. However, even with accelerated processes, some studies were completed too late for 
their results to have an early and significant impact on clinical care. This was in contrast to a 
study funded separately in 2008, which was published within a matter of weeks after the first 
two cases of 2009 A/H1N1 influenza virus infection were detected in the UK. In recognition 
of the impact of the NIHR-funded 2009 A/H1N1 influenza work and following reflection on 
the inherent delays in calling for research proposals, assessing, funding, and setting up the 
subsequent projects, including obtaining relevant ethical and regulatory approvals, the NIHR 
funded a second wave of studies in 2012. Our portfolio of projects have now been set-up 
(relevant permissions put in place, arrangements made for data collection) and pilot tested 
where relevant. All studies are now in ‘hibernation’ - that is, they have been put on standby 
mode in a maintenance-only state to await activation in the event of a pandemic being declared. 
In this thought piece, we describe the projects that were set up, the challenges of putting these 
projects into hibernation, on-going activities to maintain readiness for activation, and discuss 
how we think about planning research for a range of major incidents (e.g. other emerging 
infectious diseases, chemical, biological, radiological or nuclear (CBRN) risks, extreme 
weather events or industrial accidents). 
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Introduction 
In response to the 2009 A/H1N1 influenza pandemic, the UK’s funders, including the National 
Institute for Health Research (NIHR) rapidly sponsored and activated a number of research 
studies to inform clinical and public health actions (Table 1). That programme demonstrated 
the ability of the NIHR to commission, fund and deliver clinically relevant research under 
challenging circumstances [1]. However, even with accelerated processes, some studies were 
completed too late for their results to have an immediate significant impact on clinical care [2-
4]. This experience was shared by major research networks in other countries [5]. In contrast, 
studies which had been funded separately, either prior to the emergence of the pandemic [6] or 
via Department of Health in England were able to provide timely reports on their results [7]. 
In recognition of the impact of the NIHR-funded 2009 A/H1N1 influenza work, and following 
reflection on the inherent delays in calling for research proposals, assessing, funding and setting 
up the subsequent projects, including obtaining relevant ethical and regulatory approvals, the 
NIHR funded a second wave of studies in 2012. These projects were set up (relevant 
permissions put in place, arrangements made for data collection) and pilot tested where 
relevant.  All of the studies are being maintained in a state of readiness or ‘hibernation’ in that 
they are on standby mode in a maintenance-only state to await activation in the event of a 
pandemic being declared. Other organisations have subsequently recognised the need for better 
planning of research for future pandemics [8].  
The NIHR CRN portfolio of pandemic influenza studies 
The portfolio of studies (Table 1) cover key pathways of healthcare for influenza illness, 
including: surveillance, primary prevention (vaccination), triage (both in the community and 
at the hospital front door) and clinical management (therapeutics).  
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The population-level susceptibility, severity and spread of pandemic influenza study (PIPS) 
has developed the Health Survey for England as a tool for rapid population based serological 
surveys of influenza infection and disease [9]. During the first two waves of a pandemic, the 
study will assess the public’s susceptibility to and spread of the novel virus both geographically 
and by age. By combining our estimated number of infections in the population with estimates 
of the numbers of hospitalisations and deaths, we can quantify the proportion of infections 
leading to these outcomes – a key measure of pandemic severity.  
The Flu Telephone Survey Template study (FluTEST) has been funded to develop rapid turn-
around telephone surveys, for use in monitoring behaviour across the general population and 
identifying ways of improving how we communicate our public health advice [10]. How the 
public behave during any future pandemic will play a crucial role in how quickly influenza 
spreads in our community. Understanding whether the public are adhering to public health 
recommendations e.g. washing hands, being vaccinated and using health services 
appropriately, and if not, why not, is essential information [6][10-11]  
The EAVE (Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness) 
project has created a new sentinel system linking primary care data to RT-PCR swabs, stored 
serology and hospital and mortality outcomes. The EAVE sentinel system, which builds on the 
seasonal influenza vaccination study SIVE [12], allows rapid evaluation of any new 
vaccination (and antivirals). EAVE also provides information to help with targeting any 
available pandemic influenza vaccine at those who are considered to be at increased risk of 
serious illness or death from pandemic influenza infection e.g. those with any underlying 
medical conditions; those who may lack cross-reactivity from exposure to previous pandemics 
or vaccinations; and novel risk groups that are uniquely at risk because of a tropism exhibited 
by the virus [13]. For any new pandemic influenza vaccine, it may take some time until matched 
vaccines are available. Stockpiled pre-pandemic vaccine (e.g. H5, H7) for the UK population, 
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recommended to be of sufficient quantities for those aged 16 or under and aged 65 or over 
could be used for early testing [14,15]. 
The FLU-CATs (real time refinement and validation of criteria and tools used in primary care) 
study captures the criteria that allows validation of several triage tools in the early stage of an 
outbreak in readiness for deployment of these tools should surge occur [16]. During pandemics, 
surge in health-care demand can exceed capacity to provide normal standards of care. Health-
care workers who are unfamiliar with clinical assessment and admission decision-making may 
be asked to fulfil ‘gatekeeper’ roles. Triage tools may aid decisions in identifying people who 
are most likely to benefit from the higher levels of care that can only be provided in hospital. 
Anonymised details of patients with influenza-like-illness attending a study general practice 
will be shared with the study team. These details include: assessment, management, selected 
medical record excerpts, record hospital discharge data and death notices [16]. FLU-CATs 
activates during winter influenza seasons at a limited number of sites (5 to 20) to maintain 
study processes. This has allowed validation of the Department of Health Community 
Assessment Tools for use in children and adults presenting with seasonal influenza like illness 
The PAINTED study (PAndemic INfluenza Triage in the Emergency Department) addresses 
the issue of needing to prioritise a potentially large number of patients with limited resources 
in the event of a pandemic [17]. Clinicians will need to identify patients at higher risk of poor 
outcomes, ideally with minimal or no supplementary testing.  This study will use a standardised 
clinical assessment form to collect data on adults and children presenting to UK emergency 
departments in the event of a pandemic.  Patients will be followed up at 30 days to identify 
those who have died or needed life-saving interventions and the information collected will be 
used to evaluate current, and develop new, triage methods. 
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The UK Obstetric Surveillance System (UKOSS) influenza in pregnancy study will collect 
information on pregnant and postpartum women admitted to hospital with confirmed influenza 
infection [18]. Pregnant women are known to be at high risk of severe outcomes of a number 
of infections, and appeared disproportionately affected in the 2009 A/H1N1 influenza 
pandemic [18]. UKOSS will collect information on the management of women, focussing 
particularly on the role of extracorporeal membrane oxygenation (ECMO), and women will be 
followed up to pregnancy completion in order to collect information on both maternal and 
perinatal outcomes.  
The multi-centre Adjuvant Steroids in Adults with Pandemic Influenza (ASAP) Trial will 
determine the role of corticosteroids in adults admitted to hospital with influenza infection. 
Corticosteroids were used widely during the 2009 A/H1N1 influenza pandemic, particularly 
for severely ill patients. However increased mortality was found in observational studies [19]. 
The ASAP trial will recruit 2200 participants by the end of the first wave of the next pandemic 
with trial results available to inform clinical practice before the start of the second wave [20]. 
The Real-time modelling of a pandemic influenza outbreak (RTM) study has been funded to 
advance the state of the art of real-time modelling of influenza epidemics and to provide a tool 
to monitor and predict the development of an ongoing pandemic outbreak in the UK. Outputs 
from the RTM study include: models to produce age and region-specific epidemic forecasts 
[21]; algorithms, building on the latest developments in statistical computation, to allow 
epidemic analyses to be updated in a timely fashion as the epidemic unfolds [22]; bespoke 
software and relevant training of Public Health England (PHE) staff. 
Role of the funding source 
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The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit for publication. 
Hibernation challenges 
The need to “hibernate” studies while awaiting a pandemic is a feature of the pandemic 
influenza portfolio studies that has raised a number of issues. This reflects both the need to 
maintain interest and engagement of stakeholders (including those who initially agreed to host 
the research, policy makers and others), and changes to the landscape in terms of research 
regulations, changes in science and social changes. 
Maintaining engagement of research sites to ensure rapid activation 
Reduced research nurse availability in the event of a pandemic due to sickness absence and 
indirectly due to reallocation to clinical duties is a particular issue for several of the studies 
[17]). Furthermore, for the ASAP trial it is critical that hospital sites remain in a ‘simmering’ 
state of readiness for an extended period of time and that potential obstacles that might arise 
following activation and require ‘time-costly’ solutions are minimised [20]. For instance, there 
will be no opportunity to conduct and evaluate a pilot study once a pandemic arises. Instead, 
an activation simulation exercise was required which enabled the identification of stumbling-
blocks and refinement of trial processes, adding to trial readiness. One important issue 
highlighted was the need for ‘backup’ plans and pre-assigned ‘deputy’ roles (including for the 
Chief Investigator), as part of trial resilience [23].  
The PIPS study was specifically designed to piggyback on existing infrastructure provided by 
the Health Survey for England (HSE) [24], an annual, nationally representative, household 
survey which collects health information and blood specimens throughout the year [9]. This 
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study is therefore dependent on the long-term continuation of the HSE and its continuation 
during a pandemic.  
The RTM study’s prompt activation in the event of a pandemic depends on the continued 
commitment of relevant public bodies (e.g. PHE) and collaborators to provide ready access to 
the agreed available data. 
Approvals within a changing regulatory environment 
Studies report that research sites’ research administration staff regularly attempt to close 
hibernated studies with researchers needing to repeatedly explain the hibernation status to NHS 
organisations that are unfamiliar with the concept and do not have systems in place to 
incorporate this form of research into their regulatory frameworks. The term ‘hibernated’ thus 
possibly represents a misnomer; such studies are perhaps better thought of as ‘in progress, but 
awaiting activation of data collection’. There may be a need for new processes designed 
specifically for studies such as these. 
Dealing with changing technologies 
The PAINTED study was designed to recruit patients on the basis of clinical suspicion of 
pandemic influenza [17]. Recent advances in point of care technology mean that suspected 
seasonal influenza can be rapidly diagnosed or ruled out in the emergency department [25]. If 
applicable in a pandemic this would change the study population but would not undermine the 
need for the study or change the study design. An observational cohort study would still be 
needed to identify predictors of adverse outcome in diagnosed pandemic influenza (rather than 
suspected pandemic influenza), and therefore a modified PAINTED study with a different 
population would continue. Influenza serological assays require specialist expertise only 
available in selected laboratories that will have limited research capacity during a pandemic 
due to a substantial increase in workload. Maintaining expertise outside of these centres is 
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necessary to ensure that researchers [9] can rapidly initiate testing of samples. Pilot work 
carried out in the PIPS study identified that establishing de-novo serological testing capacity 
led to unacceptable delays. In response to this finding, the NIHR is funding short laboratory 
placements in the WHO Collaborating Centre for Reference and Research on Influenza for 
laboratory staff to maintain a pool of expertise that can be rapidly deployed. The WHO 
collaborating centre will also have access to the novel virus and the first available serological 
assay so these links will support the study’s rapid assay set up and deployment. Consideration 
is being given in how to best run rapid turn-around surveys. For example, the number of 
households that have solely mobile phones is increasing. Such households may differ from 
landline households on several demographic, and psychological levels. The FluTEST team is 
monitoring changes in the science of polling methodology and exploring the possible cost-
effectiveness of alternative approaches such as social media monitoring [26].  
Maintaining readiness of electronic platforms 
Rapid evolution of the IT landscape is inevitable so adequate resources for maintenance of such 
studies is imperative. The FLU-CATs study was established on an electronic Health Record 
(eHR) system (Vision, In Practice Systems Ltd) in partnership with the Clinical Practice 
Research Datalink [16]. The use of this platform has gradually decreased within the primary 
care community as web and cloud based systems have become more popular. To retain 
representative coverage in the UK the FLU-CATs study has been obliged to add an addition 
eHR solution which will sit on the EMIS Health eHR (Egton Medical Information Systems 
Ltd.). This will be rolled out in collaboration with the Royal College of General Practitioners 
Research and Surveillance Centre.  
The PAINTED study has been designed to use paper records, in accordance with typical NHS 
emergency department practice at the time [17]. However, increasing numbers of NHS 
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emergency departments are developing electronic data systems. The new Emergency Care Data 
Set (ECDS) has a research data item that allows identification of cases recruited to research 
and could be used to electronically flag cases included in the PAINTED study. Further pilot 
work is now required to determine whether and how the new ECDS and new emergency 
department data systems can be used to optimise data collection.  
The UKOSS research platform switched from a paper-based reporting system to an electronic 
one during the hibernation period. Additional funding to activate the study to collect 
information on seasonal influenza management and outcomes in pregnancy has enabled the 
required programming to be undertaken to maintain the hibernated pandemic influenza study 
in readiness [18]. 
Workforce issues during a pandemic 
The PIPS study is dependent on the continuation of the Health Survey for England during a 
pandemic and its ability to either maintain laboratory expertise in influenza serology or recruit 
staff with relevant experience. The data analysis protocols have been automated and could be 
run by alternative staff. A similar approach has been taken by the EAVE project whereby 
systems have been automated sufficiently for non-core staff to run the relevant syntax to extract 
and analyse data. For FLU-CATS, the study process relies on both continued activity by 
General Practitioners in Primary Care to continue their usual consultation activity for Influenza 
Like Illness using their usual Electronic Health Care Records (EHRs). The study runs on 
background processes that harvest information from these consultations. Substitution by 
locums will not inherently affect the study provided consultations continue and the EHR is 
used. The study research team is small, however the processes for data analysis have been 
archived and test activated against the current EHR systems, so could be run by substitute staff. 
For FLU-TEST, the open-access publication of the protocol and survey questions allows 
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anyone to use the FluTEST items and analyse the resulting data. For ASAP all sites and 
participating research partners (including manufacturing units) have been requested to identify 
persons who can deputise for key research staff in the event of absence from work. There is 
also an internal Pandemic Plan to ensure the project can continue to deliver the trial, including 
a “co-Chief Investigator”. PAINTED is currently exploring creating an electronic triage form 
for Emergency Department systems that could be used to collect electronic data for the study 
as part of routine clinical care. Furthermore, using record linkage to NHS Digital will allow 
the study to be undertaken with minimal research nurse support. 
Influenza pandemic preparedness and emerging infective/major incident 
challenges 
This national portfolio of hibernated pandemic influenza studies is now mature, and, we 
believe, clearly illustrates the value of the UK’s clinical research system and the potential for 
rapid research, as well as clinical and public health response, in a future pandemic. However, 
when and whether a future influenza pandemic occurs is clearly unpredictable. What is clearer, 
is that other emerging infective challenges will continue to occur.  Can these studies act as a 
model for research in a future pandemic or emerging infection?  Experience suggests they can 
as UKOSS was used to study Zika virus exposure during pregnancy [27]. 
Other hibernated studies could equally address research questions likely to be essential in any 
future epidemic or pandemic and not just those specific to influenza. For instance, the FLU-
CATS response to changes in the architecture of EHRs – the study tools could be used in either 
primary or secondary care settings for a variety of emerging diseases and 
deliberately/accidentally released agent (CBRN) (although the performance of the tool will 
vary with the population being triaged) [16]. PAINTED is focused on triage, given its 
importance in ensuring patients with suspected influenza are managed appropriately in a busy 
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emergency department setting [17]. However, a robust triage process is likely to be important 
if any other emerging infection results in large numbers of patients seeking emergency care, in 
order to ensure that the health system can function. As departments continue to face capacity 
issues, exploring the role of triage in the event of other epidemic or pandemics would be 
valuable in assessing its effectiveness in times of severe stress on health systems. 
The EAVE project has created a new sentinel system linking primary care data to RT-PCR 
swabs, stored serology and hospital and mortality outcomes. The project will allow for a rapid 
evaluation of any new vaccination irrespective of the infection it is developed to test against. 
Also, as noted above, serological analysis of stored samples on susceptibility is dependent on 
the provision of an assay that will allow this work to be undertaken. Experience of the last 
pandemic would indicate that there will likely be some delay in the development and 
deployment of such an assay. Prior agreement for access to the first assay approved for use 
would be important to maximise the study’s benefit.  
The PIPS project specimen and data collection could also be used for other epidemic/pandemic 
scenarios provided a serological marker of susceptibility/infection is available. Similarly, 
surveys using the FluTEST survey methodology could be used to monitor behaviour whatever 
the public health emergency (including CBRN risks). 
The RTM system could also be exploited in other outbreaks and, in fact, could be regularly 
used outside a pandemic to anticipate the burden of seasonal influenza. This would also test 
the easiness of its implementation and give PHE staff the opportunity to develop their expertise. 
However, use on seasonal data would pose challenges around release of relevant data (e.g. on 
general practice consultations), whose access should be instead guaranteed in the midst of a 
pandemic. 
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Irrespective of the emerging infection, trials will be needed – a network set up and ready to test 
one intervention versus standard care will be invaluable to fast track the evidence needed for 
clinical practice and the periodic activation exercise undertaken by the ASAP trial provides a 
model for this. Work has already begun to develop the ASAP Trial network for the broader 
purpose of determining the role of adjuvant corticosteroids in severe acute respiratory viral 
infections other than pandemic influenza. 
Lessons learned 
Although more information on project performance will be available once projects have been 
brought out of hibernation for testing, there have already been a number of lessons learned 
during the set-up phase. There may be a need for incremental modification in the event of 
changes in the architecture of EHRs. Approaches are needed to mitigate for reduced staff 
availability in the event of a pandemic due to sickness absence and indirectly due to reallocation 
to clinical duties e.g. pre-assigned ‘deputy’ roles and automation of processes. Commitment of 
relevant public bodies and collaborators e.g. to provide ready access to agreed available data 
should be maintained. A pool of expertise (beyond selected laboratories) that can be rapidly 
deployed is needed to carry out de-novo serological testing during pandemic. Organisational 
regulatory frameworks need to be flexible for studies that require long periods before 
activation. With technological advances for running rapid turn-around surveys, consideration 
should be given to alternative approaches that may be faster and cheaper 
Next steps 
Should the UK’s portfolio of hibernated pandemic influenza studies provide a model for how 
we think about planning research in public health emergencies, including emerging infections, 
going forward? All too often researchers are in competition when trying to answer research 
questions rapidly in an emergency situation. The research response to the Ebola outbreak in 
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West Africa was late and then inappropriately competitive resulting in several underpowered 
unsuccessful studies [28]. In contrast, the UK model allows for advance funding and planning 
of a complementary suite of studies, system testing (a test has been carried out in 2018 with 
reports compiled by the NIHR) and developing a collaborative network of researchers. Existing 
international networks e.g. the International Severe Acute Respiratory and Emerging Infection 
Consortium (ISARIC) [29] and the International Network of Obstetric Survey Systems 
(INOSS) [30] either are or could be primed and ready to go internationally with similar studies. 
The challenge going forward will be, however, for commercially funded studies not to compete 
for scarce “patient resources” and to fit within this framework to ensure the highest quality 
studies are conducted most expediently. With this in mind, is now the time for a 
national/international register of planned pandemic and emerging infection studies with 
agreements over priorities and co-enrolment and collaboration? 
Whilst an influenza pandemic heads the UK National Risk Register of Civil Emergencies [31], 
large infectious outbreaks do not constitute the only public health risk. Research to improve 
care is also essential in other public health emergencies such as natural disasters and the 
deliberate release of biochemical weapons as part of terrorist attacks [8] [32]. Coordination 
across research and funding bodies (commercial, charity and government) will be required if 
expectations demanded by the public of the research community are to be met in response to 
public health emergencies. Is this the time to consider a new way of working together as part 
of emergency preparedness, including public engagement on the ethical questions that arise? 
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Table 1 National Institute of Health Research Pandemic Influenza Preparedness Portfolio 
Project Lead Applicant and Institute Purpose of study Link 
The population-level 
susceptibility, severity and spread 
of pandemic influenza study 
(PIPS) 
Professor Andrew Hayward, 
University College London 
The PIPS study developed a system to rapidly assess real-time 
community-level susceptibility and spread of infection and illness in 
the event of a pandemic. It achieved this by adding additional 
questions and specimen collection to the Health Survey for England, 
an annual, nationally-representative survey that recruits participants 
throughout the year. 
 
https://www.ncbi.nl
m.nih.gov/books/N
BK299604/pdf/Boo
kshelf_NBK299604.
pdf  
Flu Telephone Survey Template 
study (FluTEST) 
Dr James Rubin, King’s College 
London 
The preliminary work of FluTEST involved developing, testing and 
publishing a broad range of survey questions that can be used with 
confidence in the next pandemic to identify public knowledge, 
attitudes and behaviour. During a pandemic we will support the UK 
Department of Health and Social Care in deploying these items and 
interpreting the results. 
https://www.ncbi.nl
m.nih.gov/books/N
BK263566  
Early estimation of pandemic 
influenza Antiviral and Vaccine 
Effectiveness (EAVE): use of a 
unique community and laboratory 
national linked dataset 
Professor Colin Simpson, The 
University of Edinburgh 
The EAVE project created a new sentinel system that links primary 
care data to RT-PCR swabs, stored serology and hospital and 
mortality outcome data. The project allows for a rapid evaluation of 
any new vaccination (and antivirals) and provides information to help 
with targeting any available pandemic influenza vaccine at those who 
are considered to be at increased risk of serious illness or death from 
pandemic influenza infection. 
https://www.ncbi.nl
m.nih.gov/books/N
BK321438  
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Real time refinement and 
validation of criteria and tools 
used in primary care to aid 
hospital referral decisions for 
patients of all ages in the event of 
surge during an influenza 
pandemic - FLU-CATs 
(Influenza Community 
Assessment Tools) 
Dr Malcolm (Calum) Semple, 
University of Liverpool 
FLU-CATs is a study that checks if decision tools can be used by GPs 
and other Health Care Professionals to help them choose who can be 
cared for safely in the community and who needs urgent referral to 
hospital. FLU-CATs runs each winter influenza season in a small 
number of GP practices to keep the study processes running smoothly 
and ready to react should there be a ‘new influenza’ outbreak. In the 
event of a ‘new influenza’ outbreak FLU-CATs will quickly identify 
which problems that patients have best predict the level of care that 
they need. 
 
https://www.notting
ham.ac.uk/research/
groups/healthprotect
ion/projects/flu-
cats.aspx 
 
PAndemic INfluenza Triage in 
the Emergency Department (The 
PAINTED study) 
Professor Steve Goodacre, 
University of Sheffield 
PAINTED aims to identify the most accurate triage method for 
predicting severe illness among patients attending the emergency 
department with suspected pandemic influenza.   
https://www.sheffiel
d.ac.uk/scharr/painte
d. 
Maternal and perinatal outcomes 
of pandemic influenza in 
pregnancy (UKOSS) 
Professor Marian Knight, 
University of Oxford 
The UKOSS influenza in pregnancy study will use an existing 
research platform to collect information on pregnant and postpartum 
women admitted to hospital with confirmed influenza infection. The 
management of women will be described, focussing particularly on 
the role of extracorporeal membrane oxygenation (ECMO), and 
women will be followed up to pregnancy completion in order to 
collect information on both maternal and perinatal outcomes. 
https://www.npeu.o
x.ac.uk/ukoss/curren
t-surveillance/flu  
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Multi-centre Adjuvant Steroids in 
Adults with Pandemic Influenza 
(ASAP) Trial 
Professor Wei Shen Lim, 
Nottingham University Hospitals 
The ASAP trial is a multicentre (>40 sites) blinded randomised 
controlled clinical trial to determine if low dose corticosteroids 
(dexamethasone 6mg started within 24 hours of admission once a day 
for 5 days), in addition to standard care, is associated with a lower risk 
of death or admission to intensive care, compared to placebo.  
 
https://asaptrial.org/  
Real-time Modelling of a 
Pandemic Influenza Outbreak 
(RTM) 
Dr Daniela De Angelis 
University of Cambridge 
The real time model (RTM) project advances the state of art for real 
time pandemic modelling by developing an existing model used to 
reconstruct the 2009 H1N1 pandemic on the basis of realistic 
epidemic surveillance data collected. The work for the RTM has 
already been carried out and has resulted in a new monitoring tool that 
allows to: capture spatial variation in influenza transmission; uses 
efficient computational algorithms for the provision of timely 
statistical estimates and predictions; and incorporates the above into 
freely available software. The tool is now available to Public Health 
England for use in the advent of a pandemic, and key staff has been 
trained in its use, supported by collaborators at the University of 
Cambridge to deal with workforce shortage during a pandemic. The 
real time model has been tested in the monitoring of the 2017/2018 
seasonal influenza and ready to be used in the current season to 
estimate infection and clinical attack rates and to predict timing and 
magnitude of the peak influenza activity. 
 
https://www.ncbi.nl
m.nih.gov/books/N
BK458958/pdf/Boo
kshelf_NBK458958.
pdf  
 
